Clin2
NCT07477639Possibly a fitRecruiting

Testing TRX319 for worsening multiple sclerosis

Primary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis (SPMS)Multiple SclerosisMultiple Sclerosis (MS) Primary ProgressiveMultiple Sclerosis (MS) Secondary Progressive

Treatments studied

Part of Brain & nervous system, Immune system & allergy clinical trials.

This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
39 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You must have a diagnosis of primary or secondary progressive multiple sclerosis (MS).
  • Your MS must have been getting worse in the last 2 years, and you need to be able to walk (maybe with help) but use a wheelchair only part of the time.
  • You must be between 18 and 65 years old.
  • You cannot have had a relapse in the last year, or have active infections like hepatitis, HIV, or tuberculosis.
  • You must be willing to use birth control and not donate blood for a year after the treatment.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07225504Recruiting· Phase 3
Study of remibrutinib for secondary progressive multiple sclerosis

This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.

Birmingham, Alabama
NCT07224373Recruiting· Phase 1
A study of AZD0120 for multiple sclerosis

This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.

Tucson, Arizona
NCT05704361Recruiting· Phase 1
Study of an experimental drug for multiple sclerosis

This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.

Stanford, California
NCT06961383Not yet recruiting· Phase 2
Cell therapy for worsening secondary progressive MS

This trial tests a new cell therapy (NG01) for people with secondary progressive multiple sclerosis whose disability has been worsening. It aims to see if NG01 can slow down or stop that progression.

Miami, Florida
NCT07756268Not yet recruiting· Phase 1/Phase 2
Cell therapy for multiple sclerosis

This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.

Wuhan, Hubei
NCT06171334Not yet recruiting
Remote ischemic conditioning for primary progressive MS

This study tests if a non-invasive treatment called remote ischemic conditioning can help people with primary progressive multiple sclerosis. You wear a blood pressure cuff on your arm that briefly stops blood flow and then releases it, repeated for several cycles. The goal is to see if this improves walking and other functions.

Calgary

Hear when a new Multiple sclerosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.